The FDA decision on AVT02, a proposed biosimilar to AbbVie’s Humira, is expected in September.Reykjavik, Iceland-based Alvotech Hf is developing AVT02. If approved, AVT02 will be commercialized in the U.S. by Teva Pharmaceuticals.AbbVie’s Humira is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic and psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis and ulcerative colitis. Humira, with sales of $19.83 billion, was the largest-selling blockbuster medicine worldwide in 2020. So far, 6 Humira biosimilars have been approved in the U.S. - Amgen’s, Amjevita, Boehringer Ingelheim Pharma’s Cyltezo, Novartis’ Hyrimoz, Samsung Bioepis’ Hadlima, Pfizer’s Abrilada, and Fujifilm Kyowa Kirin Biologics’ Hulio.TEVA closed Friday’s trading at $9.35, up 0.54%.